Cover Image
Market Research Report
Product code 
953721

Graft Versus Host Disease (GvHD): Forecast in Asia-Pacific Markets to 2028

Published: | GlobalData | 111 Pages | Delivery time: 1-2 business days

Price

Back to Top
Graft Versus Host Disease (GvHD): Forecast in Asia-Pacific Markets to 2028
Published: July 30, 2020
GlobalData
Content info: 111 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Graft versus host disease (GvHD) is a morbid disease and accounts for the highest cause of non-relapse mortality following allogeneic hematopoietic stem cell transplant (HSCT). Mortality is caused by either extensive tissue damage or uncontrolled opportunistic infection due to the immunosuppressive properties of the current GvHD treatment. Drug-related toxicity issues also contribute significantly to morbidity and mortality in GvHD. The GvHD market is expected to undergo significant change and growth over the next 10 years across the five growth pharmaceutical markets (5GM; India, China, Australia, South Korea, and Japan) covered in this report. In this report, GlobalData analyses the current GvHD treatment and prophylaxis landscape and provides detailed insights into the market dynamics of this newly recognized disorder. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for GvHD, and their sales projections within GvHD over the 2018-2028 forecast period.

The GvHD market is expected to undergo significant change and growth over the next 10 years across the five growth pharmaceutical markets (5GM; India, China, Australia, South Korea, and Japan) covered in this report. In this report, GlobalData analyzes the current GvHD treatment and prophylaxis landscape and provides detailed insights into the market dynamics of this newly recognized disorder. This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for GvHD, and their sales projections within GvHD over the 2018-2028 forecast period.

Currently, the GvHD prophylaxis and treatment algorithm varies significantly among physicians and institutions, largely due to the current treatment options consisting of mostly off-label therapies. Over the forecast period GlobalData expects that treatment options for GvHD patients will be expanded as pipeline products with significant clinical evidence are approved and launched for GvHD prophylaxis and treatment. The launches of products with demonstrated efficacy will be a major driver of growth over the next 10 years, other drivers of growth during this period will include.

Key Questions Answered

  • How will the GvHD prophylaxis and treatment landscape in the 5GM (India, China, Australia, South Korea and Japan) change from 2018-2028?
  • What GvHD prophylaxis agents and treatments are in clinical development?
  • How do the clinical and commercial attributes of GvHD prophylaxis and treatment candidates in development compare with one another, and against treatment options?
  • What are the remaining unmet needs in GvHD prevention and treatment?
  • What drivers and barriers will affect GvHD sales in the 5GM over the forecast period?

Scope

  • Overview of therapies used in GvHD prophylaxis in patients receiving allogenic hematopoietic stem cell transplants, and treatments for acute, chronic and steroid-refractory GvHD.
  • Topline GvHD prophylaxis and treatment market revenue from 2018-2028. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include currently available treatments and prophylaxis products, unmet needs and opportunities, and the drivers and barriers affecting GvHD sales in the 5GM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of pipeline products.
  • Analysis of the current and future market competition in the GvHD growth markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the GvHD prophylaxis and treatment in growth market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GvHD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Product Code: GDHC115POA

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Executive Summary

  • 2.1 Steady Growth Expected in the GvHD Marketplace from 2018-2028
  • 2.2 Unmet Needs Remain Largely Unattained in GvHD Management
  • 2.3 Opportunity Remains for GvHD Prophylaxis Candidates
  • 2.4 Jakavi Approval for Both Acute and Chronic GvHD Will Drive Sales
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification and Prognosis
    • 4.2.1 aGvHD
    • 4.2.2 cGvHD

5 Epidemiology

6 Current Treatment Options

  • 6.1 Overview
  • 6.2 Diagnosis
  • 6.3 Treatment

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Lack of Efficacious Treatment
  • 7.3 Lack of Treatment Options for Steroid-Refractory GvHD
  • 7.4 Identification of Patients with High- or Low-Risk Severe Disease
  • 7.5 Lack of Standardized Protocols for Prophylaxis Regimens and Off-Label Treatments

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Targeting Niche Subgroups within GvHD
    • 8.1.2 Adopting Treatments from Hematologic Indications
    • 8.1.3 Development of Kinase Inhibitors
  • 8.2 Clinical Trials Design
    • 8.2.1 Current Clinical Trial Design
    • 8.2.2 Lack of Consensus on Clinical Trial Endpoints in Current Trial Designs
    • 8.2.3 Patient Exclusion Issues in Current Clinical Trial Designs
    • 8.2.4 Limitations and Future Outlook

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Innovative Pipeline Approaches

10 Pipeline Valuation Analysis

  • 10.1 Clinical Benchmark of Key Pipeline Drugs
  • 10.2 Commercial Benchmark of Key Pipeline Drugs
  • 10.3 Competitive Assessment
  • 10.4 Top-Line 10-Year Forecast
    • 10.4.1 Australia
    • 10.4.2 India
    • 10.4.3 China
    • 10.4.4 South Korea
    • 10.4.5 Japan

11 Appendix

List of Tables

  • Table 1: GvHD: Key Metrics in the 5GM
  • Table 2: Grading System of Organ Involvement in aGvHD
  • Table 3: Global Severity of Chronic GvHD
  • Table 4: Risk Factors for GvHD
  • Table 5: Innovative Approaches for GvHD, 2019
  • Table 6: Clinical Benchmark of

List of Figures

  • Figure 1: Global (5GM) Sales Forecast for GvHD, by Country, 2018 and 2028
  • Figure 2: Competitive Assessment of the Pipeline GvHD Treatments Benchmarked Against the SOC, Corticosteroids
  • Figure 3: Pathology of Acute GvHD
  • Figure 4: 5GM, Diagno